10-K: Evommune Reports Positive Phase 2a EVO301 AD Results, IPO Fuels Growth

Evommune, a clinical-stage biotechnology company, reported positive Phase 2a results for EVO301 in atopic dermatitis and detailed its financial position following a November 2025 IPO and a February 2026 private placement.

Summary

• Evommune is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases, with lead product candidates EVO756 and EVO301 in Phase 2 development.
• EVO756, an oral small molecule antagonist of MRGPRX2, is being developed for chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), with initial results from a Phase 2 trial in chronic inducible urticaria (CIndU) showing rapid clinical activity and good tolerability.
• EVO301, a long-acting fusion protein targeting IL-18, demonstrated positive top-line results in a Phase 2a trial for moderate-to-severe AD, meeting its primary efficacy endpoint with statistical significance over placebo at weeks 4, 8, and 12 (p<0.01).
• The company completed its initial public offering (IPO) in November 2025, raising net proceeds of approximately $157.0 million.
• In February 2026, Evommune completed a private placement, selling 4,494,279 shares of common stock for gross proceeds of approximately $125.3 million.
• As of December 31, 2025, Evommune had cash, cash equivalents, and investments of approximately $216.7 million and an accumulated deficit of $221.1 million.
• Net loss for the year ended December 31, 2025, was $68.9 million, compared to $66.8 million for the year ended December 31, 2024.
• Revenue increased to $13.0 million in 2025 from $7.0 million in 2024, primarily due to higher license revenue from the Maruho Japan Agreement.
• Research and development expenses increased to $74.0 million in 2025 from $64.2 million in 2024, driven by increased clinical trial expenses for EVO756 and preclinical research, partially offset by a decrease for EVO301 due to a one-time upfront license fee in 2024.
• General and administrative expenses increased to $20.0 million in 2025 from $12.8 million in 2024, mainly due to higher personnel costs and stock-based compensation following the IPO.
• The company expects its existing cash, cash equivalents, and short-term investments to fund operating expenses and capital expenditures into the second half of 2028.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by successful clinical trial outcomes for both lead candidates and significant capital raises that extend the company's financial runway, despite ongoing losses typical for a clinical-stage biotech.

Positives

• EVO301 Phase 2a trial in moderate-to-severe Atopic Dermatitis met its primary efficacy endpoint, demonstrating clinically meaningful activity with statistical significance over placebo at weeks 4, 8, and 12 (p<0.01).
• EVO301 showed comparable efficacy to marketed AD biologics after only two doses, with sustained benefit observed 8 weeks after the final dose.
• EVO301 was well-tolerated in its Phase 2a trial, with no related serious adverse events, no treatment-related discontinuations, and no cases of conjunctivitis.
• EVO756 Phase 2 trial in CIndU demonstrated rapid clinical activity and meaningful itch relief, with 70% of observed patients showing improvement at four weeks and 30% achieving a complete response.
• EVO756 was well-tolerated in both Phase 1 and Phase 2 CIndU trials, with no serious adverse events or discontinuations due to adverse events.
• Successful completion of an IPO in November 2025, raising $157.0 million in net proceeds, significantly strengthening the company's liquidity.
• A subsequent private placement in February 2026 raised an additional $125.3 million in gross proceeds, further extending the company's cash runway.
• Increased license revenue in 2025 to $13.0 million from $7.0 million in 2024, driven by development milestones from the Maruho Japan Agreement.
• Management expects existing cash, cash equivalents, and short-term investments to fund operations into the second half of 2028.

Negatives

• The company has a limited operating history and no products approved for commercial sale, having incurred net losses in every year since inception, with an accumulated deficit of $221.1 million as of December 31, 2025.
• Net loss increased to $68.9 million in 2025 from $66.8 million in 2024.
• The company will need substantial additional funding beyond 2028 to continue operations and advance product candidates, with no committed external source of funds.
• Reliance on third-party manufacturers, CROs, CDMOs, and suppliers introduces risks related to supply, quality, regulatory compliance, and potential disruptions.
• The company faces intense competition from larger, more resourced biotechnology and pharmaceutical companies.
• The market acceptance of any approved product candidates is uncertain and depends on various factors, including efficacy, safety, cost, and reimbursement.
• Two subjects in the EVO756 300 mg QD cohort experienced asymptomatic transaminase elevations (increased ALT and AST) greater than ten times the upper limit of normal, though these later returned to baseline and had confounding factors.

Risks

• Need for substantial additional funding to maintain operations and advance product candidates; failure to obtain capital may force delays or elimination of research and development.
• Prioritization of certain product candidates due to limited resources may divert from better opportunities or adversely affect commercial success.
• Preclinical and clinical drug development is lengthy, expensive, and uncertain; prolonged or delayed trials may prevent timely regulatory approvals.
• Clinical trials may fail to demonstrate substantial evidence of safety and efficacy, preventing or limiting regulatory approval and commercialization.
• Product candidates may be associated with serious adverse side effects or safety risks, leading to delays, denial of approval, or limited market demand.
• Extensive regulatory and compliance obligations are costly and time-consuming, potentially causing unanticipated delays or preventing approvals.
• Lack of internal marketing, sales, or distribution capabilities requires significant investment or reliance on third parties, which may not generate sufficient product revenue.
• Significant competition from other biotechnology and pharmaceutical companies could lead to operating losses if the company fails to compete effectively.
• Reliance on third-party manufacturers, CROs, CDMOs, and suppliers poses risks of loss, non-compliance, insufficient supply, or quality issues.
• High dependence on senior management team; inability to retain key personnel or recruit additional qualified staff could harm the business.
• Existing and future collaborations may not be successful, impacting business if new collaborations are not formed or existing ones fail.
• Licensed intellectual property rights from third parties may be subject to early termination if obligations are not met, leading to loss of material rights.
• Potential for information technology systems or data to be compromised by cyber threats, leading to regulatory actions, litigation, fines, business disruptions, and reputational harm.
• Stringent and evolving U.S. and foreign data privacy and security laws, regulations, and contractual obligations could lead to enforcement actions, litigation, and business disruptions.
• Ability to use U.S. net operating loss carryforwards and other tax attributes may be limited by ownership changes under Section 382 and 383 of the Internal Revenue Code.
• Changes in U.S. tax law, such as the One Big Beautiful Bill Act, may adversely affect the business, cash flow, financial condition, or results of operations.
• Adverse effects from earthquakes, fires, or other natural disasters on facilities or supply chain, with business continuity and disaster recovery plans potentially inadequate.
• Product liability lawsuits could result in substantial liabilities, limit commercialization, and may not be fully covered by insurance.
• Difficulties in managing organizational growth, including hiring and integrating personnel, could disrupt operations.
• Misconduct or improper activities by employees, principal investigators, consultants, and commercial partners, including non-compliance with regulatory standards and insider trading, could lead to severe penalties.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business, particularly reliance on foreign suppliers and CROs.
• Ongoing regulatory obligations and continued review post-approval may result in significant additional expense, labeling restrictions, or market withdrawal.
• Future growth depends on commercializing products in foreign markets, subject to additional regulatory burdens and risks.
• Uncertainty regarding new U.S. administration initiatives and their impact on the FDA, regulations, and healthcare costs, potentially delaying approvals or affecting commercialization.
• Difficulty and cost in protecting proprietary rights and technology, with no guarantee of patent issuance, validity, or enforceability against third-party challenges.
• Reliance on trade secrets and proprietary know-how, which are difficult to trace and enforce, increasing risk of misappropriation or disclosure by competitors or third parties.
• Changes in U.S. or foreign patent law could diminish the value of patents, impairing ability to protect product candidates.
• Involvement in lawsuits or proceedings to protect or enforce intellectual property could be expensive, time-consuming, and unsuccessful.
• Risk of not identifying relevant third-party patents or incorrectly interpreting their relevance, scope, or expiration date, affecting ability to develop and market products.
• Inability to obtain or maintain necessary rights to product candidates through acquisitions and in-licenses on reasonable terms.
• Intellectual property licensed from third parties may be subject to retained rights by licensors or government agencies, potentially limiting commercialization.

Future Outlook

Evommune expects to continue incurring significant net losses for the foreseeable future as it advances EVO756 and EVO301 through clinical development and expands its research and development efforts. Initial results from the Phase 2b trial of EVO756 in CSU are expected in the second quarter of 2026, and initial results from the Phase 2b trial of EVO756 in moderate-to-severe AD are expected in the second half of 2026. The company plans to rapidly move a subcutaneous formulation of EVO301 into a Phase 2b trial in AD and evaluate EVO301 in moderate-to-severe UC patients. A Phase 2b trial for EVO756 in migraine is planned for mid-2026. Evommune anticipates its current cash, cash equivalents, and investments will fund operations into the second half of 2028, but substantial additional funding will be required thereafter.

Management Comments

• Our mission is to improve patients daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies.
• By identifying treatment gaps of chronic inflammatory diseases, we strive to transform the treatment landscape, developing therapies that have the potential to offer rapid symptom relief and provide safe, durable resolution of the underlying disease.
• We believe EVO756 is the only dual mechanism clinical approach that modulates both mast cells and peripheral sensory neurons, representing a new potential therapeutic option to reduce inflammation and provide rapid relief of itch (pruritus).
• We believe MRGPRX2 is the only clinical approach aimed at inhibiting this neuroimmune interaction.
• We believe EVO756s clinical activity in symptomatic dermographism patients strongly supports the role of MRGPRX2 in neurogenic inflammation, which plays a crucial role in AD.
• We believe EVO301s optimized approach to IL-18 binding and neutralization could enable significant advantages and differentiated clinical outcomes for patients, including with respect to efficacy, tissue distribution, dosing profile and reduced immunogenicity risk.
• We believe demonstrating this activity with an IL-18 targeting therapy supports the relevance of this pathway in disease pathophysiology and reinforces that pathways beyond classic Th2 biology can contribute meaningfully to disease activity.
• Expanding therapeutics to target novel mechanisms like IL 18 could offer benefit for patients who remain uncontrolled on existing therapies and reinforces the urgent need to develop more options across the growing AD population.
• We plan to rapidly move a subcutaneous formulation of EVO301 into a Phase 2b trial in AD where we believe optimized and more frequent dosing of EVO301 could achieve potential best-in-class Eczema Area and Severity Index (EASI) activity.
• Our management team has deep expertise with MRGPRX2, having worked with the target for over a decade, which we believe provides us with powerful insight into the biology, patient needs and treatment landscape in this space.
• We believe EVO756 can be a first-line therapy for CSU and AD and is currently the most advanced program in clinical development targeting MRGPRX2.
• We believe EVO756s carefully designed molecular and PK profile, with high bioavailability and limited off-target potential, differentiates it from other known attempts to mechanistically target MRGPRX2 in chronic inflammatory diseases.
• We believe this PD assessment provides proof-of-concept for EVO756 in the treatment of CU as EVO756 was observed to engage MRGPRX2, block the impact of a known MRGPRX2 ligand and robustly reduce the mean size of icatibant-induced wheals.
• We believe EVO756 may ultimately be a first line treatment option across prescriber types, if approved.
• We believe that MRGPRX2-targeted therapies have the potential to show a superior safety and comparable efficacy profile to Xolair, Dupixent, Rhapsido, and other therapeutic candidates in development, thus having the potential to become the first-line treatment for antihistamine-refractory patients.
• We believe the safety results observed to-date and convenient oral dosing of EVO756 may not only position it to become the backbone therapy for CSU, if approved, but it also has the potential to be used in combination treatment with existing approved biologics, such as Xolair and Dupixent.
• We believe MRGPRX2 is the only target currently being pursued clinically that impacts both mast cells and neuroinflammation, making it uniquely positioned as a potential therapy for AD.
• We believe the market for AD therapeutics is in a nascent stage, particularly when compared to the growth observed in the market for psoriasis.
• We believe a treatment option with this product profile would have broad applicability, first-line potential in moderate-to-severe disease and could be utilized by a wider range of prescribers, expanding access.
• We believe MRGPRX2 is the only target impacting both mast cells and neuroinflammation, two key factors underlying AD.
• We believe EVO756 has the potential to address several additional chronic inflammatory diseases.
• We believe EVO301s differentiated profile may enable it to become a leading therapy for a broad range of chronic inflammatory diseases.
• We believe this design, differentiated from mAbs targeting IL-18, potentially confers several advantages including improved activity, decreased immunogenicity and better distribution to sites of inflammation.
• We believe EVO301s distinct mechanism and modality complement those of EVO756, providing us with multiple potential avenues to bring innovative therapeutics to the large, underserved and rapidly expanding patient population suffering from chronic inflammatory diseases.
• We believe IL-18 is the only target impacting broader immunological cascades of Th2, Th1, Th17, Innate Inflammation and IL-22, key factors underlying AD.

Industry Context

StockSavvy.ai notes that Evommune operates in the highly competitive and rapidly innovating biotechnology and biopharmaceutical industries, specifically targeting chronic inflammatory diseases. The company's dual-mechanism approach with EVO756 (MRGPRX2 antagonist) and EVO301 (IL-18BP fusion protein) aims to address significant unmet needs in large patient populations for conditions like CSU, AD, and UC. The market for AD therapeutics is described as nascent, suggesting substantial growth potential, similar to the historical expansion seen in the psoriasis market. Evommune's strategy of targeting novel mechanisms like IL-18 and MRGPRX2 positions it to potentially offer differentiated therapies for patients who do not respond adequately to existing treatments, which often have limitations in efficacy, safety, or convenience (e.g., Xolair, Dupixent, Rhapsido). The company's reliance on third-party manufacturing and CROs is a common industry practice but also a source of risk, as highlighted in the filing.

Comparison to Industry Standards

• EVO756's average reduction of 1.4 points in FricTest score (300 mg QD cohort) and 1.5 points (50 mg BID cohort) after four weeks in CIndU is comparable to third-party trials of 300 mg omalizumab (1.4 points reduction) and 300 mg barzolvolimab (1.6 points reduction) in CIndU patients with symptomatic dermographism.
• EVO301 achieved comparable improvement in EASI from baseline to other approved AD biologics (e.g., Dupixent, Rinvoq, Cibinqo) after only two doses in its Phase 2a trial, despite these comparators being administered under fully optimized dosing regimens. Dupixent achieved 36% EASI-90 in 16 weeks, while Rinvoq and Cibinqo achieved over 40% EASI-90 at 16 weeks. EVO301's vIGA-AD 0/1 response rate was approximately 23% at week 12 (vs 0% placebo).
• EVO301's Phase 2a trial reported no cases of conjunctivitis, a potential side effect observed with other biologics in AD, such as Dupixent.
• Existing treatments for antihistamine-refractory CSU, such as Xolair, Dupixent, and Rhapsido, have limitations including safety concerns (e.g., Xolair's black box warning for anaphylaxis, JAK inhibitors' boxed warnings on cardiac events and malignancies), limited efficacy (e.g., Dupixent's less than a third complete response rate at week 24 in Xolair-naive patients), and burdensome administration or side effects (e.g., Xolair's in-office administration, Rhapsido's adverse reactions like nasopharyngitis, bleeding, headache, nausea, abdominal pain). Evommune believes EVO756 has the potential for a superior safety and comparable efficacy profile.
• KIT inhibitors, also in development for CSU, impact the development of a range of other cells, leading to side effects like neutropenia, changes in taste and hair color, and spermatogenesis, which Evommune believes could limit them to later-line treatment options.

Corporate Governance

Legal Proceedings

• Not currently a party to any litigation or legal proceedings that are probable to have a material adverse effect on the business. Litigation can have an adverse impact on business, financial condition, results of operations, and prospects due to defense and settlement costs, and diversion of management resources.

Related Party Transactions

• In December 2020, Evommune entered into a License, Development and Commercialization Agreement with Dermira, Inc. (a wholly owned subsidiary of Eli Lilly and Company), paying a $7.5 million upfront license fee and issuing 3,227,805 shares of Series A Preferred Stock (approximately 5% of fully diluted equity at the time). Evommune is obligated to pay Dermira up to $45.0 million in development milestones for EVO756 (or $135.0 million for all licensed products) and up to $240.0 million in sales milestones for EVO756 (or $720.0 million for all licensed products), plus tiered royalties.
• As of December 31, 2025, Evommune paid a total of $11.0 million in upfront payments and development milestones under the Dermira License Agreement, with $2.5 million recognized as R&D expense in 2025.
• In September 2023, Evommune entered into a sublicense agreement with Maruho Co., Ltd. for EVO756 in Japan, receiving an $8.0 million upfront payment and eligible for up to $52.0 million in additional milestones and low single-digit royalties. As of December 31, 2025, $18.0 million has been received, including a $10.0 million development milestone in July 2025.
• In March 2024, Evommune entered into a second sublicense agreement with Maruho for EVO756 in Greater China and other Asian countries, receiving a $7.0 million upfront payment and eligible for up to $54.5 million in additional milestones and low single-digit royalties. As of December 31, 2025, $7.0 million has been received.
• In June 2024, Evommune entered into a license agreement with AprilBio Co., Ltd. for EVO301, paying an upfront payment of $15.0 million (expensed in 2024) and obligated to pay up to $82.5 million in development milestones, $377.5 million in sales milestones, and tiered mid-to-high single-digit royalties. For 2025, $1.5 million was recorded as R&D expense for a development milestone.

Stakeholder Impact

• Shareholders: The successful IPO and private placement have significantly increased capital, reducing immediate funding risks and potentially supporting long-term value creation through continued product development. However, future equity offerings could dilute existing shareholders. The stock price may be volatile due to clinical trial results and market factors.
• Employees: The company's growth and continued R&D efforts will likely lead to increased headcount and personnel-related costs, including stock-based compensation, which can incentivize and retain talent. The insider trading policy and recoupment policy aim to ensure ethical conduct and accountability.
• Customers (future patients): The development of EVO756 and EVO301 aims to provide innovative therapies for chronic inflammatory diseases, potentially improving quality of life and addressing unmet medical needs for millions of patients.
• Suppliers/CROs/CDMOs: Continued reliance on third-party organizations for manufacturing and clinical trials provides business opportunities for these partners, but also exposes the company to supply chain and compliance risks.
• Creditors: The increased cash position from capital raises improves the company's financial stability and ability to meet its obligations.

Next Steps

• Report initial results from the Phase 2b dose-ranging trial of EVO756 in CSU in the second quarter of 2026.
• Report initial results from the Phase 2b dose-ranging trial of EVO756 in moderate-to-severe AD patients in the second half of 2026.
• Initiate a Phase 2b trial of EVO756 in migraine in mid-2026.
• Rapidly move a subcutaneous formulation of EVO301 into a Phase 2b trial in AD.
• Evaluate a potential Phase 2 trial of EVO301 in moderate-to-severe UC patients.
• Evaluate EVO301 in Crohn's disease, certain cardiovascular-related inflammatory conditions, and additional indications.
• Advance additional preclinical programs into clinical development, with possible nomination of lead development candidates for IND-enabling studies in 2026 and beyond.
• Continue evaluating potential preclinical assets, including through in-licensing or partnerships, to broaden the portfolio.

Key Dates

Recommendation

Evommune has demonstrated promising clinical results for both EVO756 and EVO301, particularly the statistically significant efficacy of EVO301 in Phase 2a AD and the rapid activity of EVO756 in CIndU. The recent IPO and private placement have substantially bolstered the company's cash position, providing a runway into the second half of 2028. These are strong positive indicators for a clinical-stage biotechnology company. However, the company remains unprofitable, with significant ongoing R&D expenses and an accumulated deficit. The path to commercialization is long, expensive, and uncertain, with inherent risks in clinical development, regulatory approval, market acceptance, and intense competition. While the positive clinical data and strong liquidity are encouraging, the speculative nature of biotech investments and the early stage of product development warrant a 'hold' recommendation for seasoned investors, awaiting further de-risking through later-stage clinical trials and clearer paths to profitability.

Keywords

Biotechnology, Clinical-stage, Inflammatory diseases, Atopic dermatitis, Chronic spontaneous urticaria, Ulcerative colitis, EVO756, EVO301, MRGPRX2 antagonist, IL-18 binding protein, Phase 2 trials, IPO, Drug development, Immunology, Neuroinflammation, Mast cells, SEC filing, Financial results, Capital raise